Anhui Huaheng Biotechnology Stock EBITDA

688639 Stock   32.61  0.34  1.03%   
Anhui Huaheng Biotechnology fundamentals help investors to digest information that contributes to Anhui Huaheng's financial success or failures. It also enables traders to predict the movement of Anhui Stock. The fundamental analysis module provides a way to measure Anhui Huaheng's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anhui Huaheng stock.
Last ReportedProjected for Next Year
EBITDA275.3 M220.1 M
As of December 27, 2024, EBITDA is expected to decline to about 220.1 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Anhui Huaheng Biotechnology Company EBITDA Analysis

Anhui Huaheng's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Anhui Huaheng EBITDA

    
  482.93 M  
Most of Anhui Huaheng's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anhui Huaheng Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

Anhui Ebitda

Ebitda

220.06 Million

At present, Anhui Huaheng's EBITDA is projected to increase significantly based on the last few years of reporting.
According to the company disclosure, Anhui Huaheng Biotechnology reported earnings before interest,tax, depreciation and amortization of 482.93 M. This is 44.96% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all China stocks is 87.61% higher than that of the company.

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Anhui Fundamentals

About Anhui Huaheng Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Anhui Huaheng Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anhui Huaheng using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anhui Huaheng Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Anhui Stock

Anhui Huaheng financial ratios help investors to determine whether Anhui Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anhui with respect to the benefits of owning Anhui Huaheng security.